good news. Whether it helps us this morning or not who knows but at least they're on track. Kyowa has also completed the gastric trial so results from that should be available by end of year. The abstracts looked good to me...in particular HCC and melanoma but yesterday's market was in no humor for anything and certainly not small biotechs. On positive side, ARQL mang is executing to plan...the results will have to speak for themselves.